Notably, Siv@NMs treatment achieved significantly greater reductions in MPO-DNA, H3cit, TNFα, and IL-6 levels, further validating the enhanced therapeutic efficacy of the nanoparticle formulation in suppressing systemic NETosis and inflammation during sepsis. The gene discussed is IL6; the disease is Sepsis.